title: Macular infarction following intravitreal bevacizumab for treatment of central retinal vein occlusion.
abstract: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is widely used for the treatment of macular edema associated with central retinal vein occlusion (CRVO). The authors present a series of three patients with CRVO who suffered apparent macular infarction within weeks of intravitreal administration of bevacizumab. Of the nearly 200 patients undergoing intravitreal injections of bevacizumab for this indication over a surveillance period of 3 years, this event occurred in three patients. This has not been described in the natural history of the disease and is associated with poor visual outcomes.
authors: Department of Ophthalmology, Stanford University School of Medicine, California, USA.
authors: Loh-Shan B
authors: LS
authors: Leung
authors: Ruwan A
authors: RA
authors: Silva
authors: Mark S
authors: MS
authors: Blumenkranz
authors: Harry W
authors: HW
authors: Flynn
authors: Steven R
authors: SR
authors: Sanislo
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007238:Infarction / Q000139:chemically induced*; D058449:Intravitreal Injections / Q000009:adverse effects; D008266:Macula Lutea / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D012164:Retinal Diseases / Q000139:chemically induced*; D012170:Retinal Vein Occlusion / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab